GenomOncology to Present at Cleveland Clinic Medical Innovation Summit
News Oct 25, 2014
GenomOncology has announced that Manuel Glynias, the company’s President and CEO, will be presenting a corporate overview at the Cleveland Clinic’s 2014 Medical Innovation Summit to be held October 26-29 in Cleveland, IL.
The presentation will take place on Wednesday October 29 at 8:25 ET at the Cleveland Convention Center in Room 26. There will be a breakout for Q&A immediately following the presentation in Room 23.
GenomOncology is focused on enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. The company’s proprietary technology platform, GO Clinical Workbench, streamlines the use of NGS data in conjunction with other analytic modalities and allows clinical laboratories to produce an actionable clinical report using the molecular profile of an individual patient’s tumor.
“I was pleased to be invited to participate in the Cleveland Clinic’s Medical Innovation Summit,” commented Manuel Glynias. “Translating the vast amounts of data from next-generation sequencing into useful information for clinical use is of the utmost importance. GenomOncology is dedicated to expanding the availability of this information to the industry and welcomes the opportunity to share ideas with conference attendees.”
Mr. Glynias is a serial entrepreneur with over 25 years of experience in bioinformatics. Immediately prior to GenomOncology, Manuel was a partner at Rosetta, a leading interactive marketing agency, where he helped develop big data solutions for ecommerce clients.
In the late 90’s, Manuel was the founder and CEO of NetGenics, a venture-backed provider of discovery informatics to the biopharmaceutical industry and academic research centers. He also developed a number of other commercial software platforms including MacGene, Gene Works, and Primer Express. Manuel has an AB in Biochemistry and Molecular Biology from Harvard College.
An artificial intelligence (AI) approach based on deep learning convolutional neural network (CNN) could identify nuanced mammographic imaging features specific for recalled but benign (false-positive) mammograms and distinguish such mammograms from those identified as malignant or negative.
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
Scientists have developed a successful method to make truly personalized predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms.
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019